← Back to all signals
RESEARCH PAPER ANALYSIS

The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.

AI interpretation is pending for this paper.

Open original publication →
PMID41015051
JournalLancet (London, England)
Publication Date2025-09-24
Ingested2026-08-02 12:05 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Cancer is a leading cause of death globally. Accurate cancer burden information is crucial for policy planning, but many countries do not have up-to-date cancer surveillance data. To inform global cancer-control efforts, we used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 framework to generate and analyse estimates of cancer burden for 47 cancer types or groupings by age, sex, and 204 countries and territories from 1990 to 2023, cancer burden attributable to selected risk factors from 1990 to 2023, and forecasted cancer burden up to 2050. METHODS: Cancer estimation in GBD 2023 used data from population-based cancer registration systems, vital registration systems, and verbal autopsies. Cancer mortality was estimated using ensemble models, with incidence informed by mortality estimates and mortality-to-incidence ratios (MIRs). Prevalence estimates were generated from modelled survival estimates, then multiplied by disability weights to estimate years lived with disability (YLDs). Years of life lost (YLLs) were estimated by multiplying age-specific cancer deaths by the GBD standard life expectancy at the age of death. Disability-adjusted life-years (DALYs) were calculated as the sum of YLLs and YLDs. We used the GBD 2023 comparative risk assessment framework to estimate cancer burden attributable to 44 behavioural, environmental and occupational, and metabolic risk factors. To forecast cancer burden from 2024 to 2050, we used the GBD 2023 forecasting framework, which included forecasts of relevant risk factor exposures and used Socio-demographic Index as a covariate for forecasting the proportion of each cancer not affected by these risk factors. Progress towards the UN Sustainable Development Goal (SDG) target 3.4 aim to reduce non-communicable disease mortality by a third between 2015 and 2030 was estimated for cancer. FINDINGS: In 2023, excluding non-melanoma skin cancers, there were 18·5 million (95% uncertainty interval 16·4 to 20·7) incident cases of cancer and 10·4 million (9·65 to 10·9) deaths, contributing to 271 million (255 to 285) DALYs globally. Of these, 57·9% (56·1 to 59·8) of incident cases and 65·8% (64·3 to 67·6) of cancer deaths occurred in low-income to upper-middle-income countries based on World Bank income group classifications. Cancer was the second leading cause of deaths globally in 2023 after cardiovascular diseases. There were 4·33 million (3·85 to 4·78) risk-attributable cancer deaths globally in 2023, comprising 41·7% (37·8 to 45·4) of all cancer deaths. Risk-attributable cancer deaths increased by 72·3% (57·1 to 86·8) from 1990 to 2023, whereas overall global cancer deaths increased by 74·3% (62·2 to 86·2) over the same period. The reference forecasts (the most likely future) estimate that in 2050 there will be 30·5 million (22·9 to 38·9) cases and 18·6 million (15·6 to 21·5) deaths from cancer globally, 60·7% (41·9 to 80·6) and 74·5% (50·1 to 104·2) increases from 2024, respectively. These forecasted increases in deaths are greater in low-income and middle-income countries (90·6% [61·0 to 127·0]) compared with high-income countries (42·8% [28·3 to 58·6]). Most of these increases are likely due to demographic changes, as age-standardised death rates are forecast to change by -5·6% (-12·8 to 4·6) between 2024 and 2050 globally. Between 2015 and 2030, the probability of dying due to cancer between the ages of 30 years and 70 years was forecasted to have a relative decrease of 6·5% (3·2 to 10·3). INTERPRETATION: Cancer is a major contributor to global disease burden, with increasing numbers of cases and deaths forecasted up to 2050 and a disproportionate growth in burden in countries with scarce resources. The decline in age-standardised mortality rates from cancer is encouraging but insufficient to meet the SDG target set for 2030. Effectively and sustainably addressing cancer burden globally will require comprehensive national and international efforts that consider health systems and context in the development and implementation of cancer-control strategies across the continuum of prevention, diagnosis, and treatment. FUNDING: Gates Foundation, St Jude Children's Research Hospital, and St Baldrick's Foundation.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Analysis of Ocular Surface Tumours and Lesions by High-definition Anterior-segment Optical Coherence Tomography. Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 70.6 2 Preliminary Validation of a Self-Reported Functional Outcomes Tool for Children with Extremity Tumors: Translation into Persian and Assessment of the Reliability and Validity of the pTESS-Leg Questionnaire. Medical journal of the Islamic Republic of Iran 58.4 3 Metastatic HER2-positive breast cancer in a 19-year-old woman following a 4-year diagnostic delay: a case report. AME case reports 55.4 4 A hepatic malignant spindle-cell neoplasm of uncertain lineage clinically favoring sarcomatoid hepatocellular carcinoma: a case report. AME case reports 58.2 5 Second-Course Reirradiation Versus No Reirradiation in Pediatric Diffuse Intrinsic Pontine Glioma: A Meta-Analysis of Survival Outcomes. Pediatric neurology 81.62 6 Role of genomic testing in modern diagnostic surgical pathology practice. Pathology 62.3 7 Asperginase-based chemotherapy regimen for acute lymphoblastic leukemia: A cohort study with promising outcomes on adults. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 77.34 8 Pediatric lymphomatoid papulosis: a broad clinicopathologic spectrum including rare variants in a single-center case series. Frontiers in medicine 57.8 9 Safety and surgical outcomes of sodium fluorescein-guided pediatric brain tumor surgery: a retrospective before-and-after single-center cohort study. Frontiers in surgery 61.7 10 URGCP promotes osteosarcoma progression by regulating the ESCRT-III subunit CHMP4B. Translational cancer research 55.8 11 Sequential chemoradiotherapy vs. radiotherapy alone or concurrent chemoradiotherapy after radical resection of stage IA2-IIA1 cervical cancer: a retrospective cohort study. Translational cancer research 77.74 12 Lnc-TIM3 promotes acute lymphoblastic leukemia progression through miR-5094-mediated regulation of TIM3. Translational cancer research 52.9 13 [Adherence to Hepatocellular Carcinoma Surveillance and Its Association with Tumor Stage at Diagnosis: Experience at a University Hospital]. Acta gastroenterologica Latinoamericana 67.0 14 Quantitative and qualitative magnetic resonance imaging-based analysis to predict postoperative disease progression in hepatocellular carcinoma. Medical physics 63.7 15 Cross-Sectional Profiling of Aqueous Humor VEGF-A Reflects the Tumor and Ocular Microenvironment in Retinoblastoma. Investigative ophthalmology & visual science 64.4 16 What is in the Dust? Species-Level Profiling Reveals Pathogenic and Protective Potential of Microbial Communities in Daycare and Home Environments. Environmental microbiology reports 37.0 17 Successful management of long-term venovenous ECMO for severe PARDS in a child with acute lymphoblastic leukemia. Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs 57.6 18 Ovarian Yolk Sac Tumor in a 10-Year-Old Girl Following Metachronous Bilateral Mature Ovarian Teratomas. Case reports in obstetrics and gynecology 60.4 19 High-risk Human Papillomavirus Genotypes in Women Undergoing Cervical Screening in Leshan, China: Real-time and Nested Multiplex PCR. Journal of visualized experiments : JoVE 61.0 20 Generation of an Induced Pluripotent Stem Cell Line from a Patient with Infantile Liver Failure Syndrome 2 Carrying a Compound Heterozygous Mutation in NBAS. Cellular reprogramming 46.5 21 Targeted pharmacotherapy of NF1-associated plexiform neurofibromas: current evidence and future perspectives. Expert opinion on pharmacotherapy 69.44 22 Hijacking Developmental Immunity: Inflammation and Immune Dysregulation in Pediatric Brain Tumors. Neuro-oncology 63.6 23 MGMT expression in pediatric H3 G34-mutant diffuse hemispheric glioma: technical covariates should be addressed before clinical use. Acta neuropathologica 47.5 24 Poor mental health days and depressive disorders comparing non-caregivers, informal non-cancer caregivers, and informal caregivers of cancer patients: BRFSS 2022-23. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 65.5 25 Paediatric thalamic tumours: a predictive MR phenotype. Neuroradiology 59.5 26 International patterns and incidence trends of lung cancer in adolescent and young adults by histological subtype and sex. Annals of the American Thoracic Society 57.5 27 PAX3::FOXO1 and the INO80 complex sustain replication fork progression in fusion positive rhabdomyosarcoma. Molecular cancer research : MCR 48.5 28 Prevalence and geographical distribution of persons with albinism (PWA) in Togo in 2024. PloS one 59.0 29 Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 83.4 30 Erratum: Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 47.5 31 Genetic hepatocellular cholestasis: an update. Clinics and research in hepatology and gastroenterology 66.0 32 It Is Possible to Save the Kidney With Renal Artery Occlusion Without Autotransplantation: A Case Report. Transplantation proceedings 45.5
PATIENT-FRIENDLY SUMMARY

The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic